Menu
Home / Guides / NexLife’s FDA warning letter
In FDA’s words, plus NexLife’s response and status
NexLife’s FDA warning letter 730096: what FDA said, the response and the status
Published by NexLife · Updated
On June 8, 2026, the U.S. Food and Drug Administration (FDA) sent NexLife warning letter MARCS-CMS 730096 about claims on the nexlife.us website. NexLife submitted a formal written response to FDA and has implemented corrective actions. As of Nov. 12, 2026, FDA has not published a close-out letter for Warning Letter 730096, and NexLife does not state that FDA has formally closed or resolved the matter.
Status as of Nov. 12, 2026
FDA has not published a close-out letter
- Warning letter
- MARCS-CMS 730096
- Issued
- June 8, 2026, by FDA’s Center for Drug Evaluation and Research
- Posted by FDA
- June 16, 2026
- NexLife’s response
- Formal written response submitted (most recent: Sept. 21, 2026)
- Corrective actions
- Implemented; review of medication-related content continues
At a glance
FDA warning letter 730096, at a glance
The letter, NexLife’s response and the status, with their dates.
| Question | Answer |
|---|---|
| The letter | Warning letter MARCS-CMS 730096, dated June 8, 2026 |
| From | FDA’s Center for Drug Evaluation and Research, Office of Compounding Quality and Compliance |
| To | Nexlife Inc. dba Nexlife |
| What FDA reviewed | The nexlife.us website, in March 2026 |
| What FDA said | That the website’s representations about compounded semaglutide and tirzepatide were false or misleading, including pictured labels that identified “Nexlife” as if it were the compounder |
| The law FDA cited | Sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act: the products were misbranded, FDA said |
| Posted by FDA | June 16, 2026, on FDA’s warning letters page |
| NexLife’s response | A formal written response to FDA describing corrective actions; the most recent is dated Sept. 21, 2026 |
| Status | Corrective actions implemented; review of medication-related content continues. No close-out letter published as of Nov. 12, 2026 |
From FDA’s posted letter and NexLife’s own records; status checked Nov. 15, 2026.
Key takeaways
- What happened: FDA sent NexLife warning letter 730096 on June 8, 2026, after reviewing the nexlife.us website, and posted it on June 16.
- FDA’s concern: pictured labels identified “Nexlife,” “suggesting Nexlife is the compounder of those drugs when in fact it is not,” FDA wrote.
- The law: FDA said the website’s representations were false or misleading, which made the products misbranded under sections 502(a) and 502(bb) of the FD&C Act.
- NexLife’s response: NexLife submitted a formal written response to FDA, most recently on Sept. 21, 2026. It described corrective actions taken regarding product imagery, website representations, compounded-medication disclosures, and claims concerning FDA approval and FDA-approved branded products.
- Status: NexLife has implemented corrective actions and continues to review medication-related content for regulatory compliance. As of Nov. 12, 2026, FDA has not published a close-out letter for Warning Letter 730096. NexLife does not state that FDA has formally closed or resolved the matter.
In FDA’s words
What did FDA’s warning letter to NexLife say?
The letter is about how the website presented compounded medicines: its claims and the labels it pictured.
FDA’s Office of Compounding Quality and Compliance wrote that the letter followed a review of the nexlife.us website in March 2026, where NexLife offered compounded semaglutide and tirzepatide. These are its main points, quoted from the letter:
“Your representations regarding compounded semaglutide and tirzepatide products are false or misleading.”
FDA warning letter 730096, June 8, 2026The labels pictured on the website identified “Nexlife,” “suggesting Nexlife is the compounder of those drugs when in fact it is not.”
FDA warning letter 730096FDA said these representations cause the compounded drug products “to be misbranded under sections 502(a) and 502(bb) of the FD&C Act.”
FDA warning letter 730096In a footnote, FDA noted that the labels of the drug products as depicted on the website “do not indicate that they are dispensed under section 503(b)(1) of the FD&C Act,” the section for prescription drugs, “nor do they appear to comply with the requirements of section 503(b)(2).”
FDA warning letter 730096, footnoteWhat those sections mean, in the law’s own words: under section 502(a)(1), a drug is misbranded “if its labeling is false or misleading in any particular,” and under section 502(bb), “if the advertising or promotion of a compounded drug is false or misleading in any particular” (21 U.S.C. 352). The letter asked NexLife to “promptly address the violations” and to answer in writing within 15 business days.
NexLife’s response
How did NexLife respond to the warning letter?
In writing, to the U.S. Food and Drug Administration.
NexLife submitted a formal written response to the U.S. Food and Drug Administration. Its most recent formal written response is dated Sept. 21, 2026. The response described corrective actions taken regarding:
- product imagery,
- website representations,
- compounded-medication disclosures, and
- claims concerning FDA approval and FDA-approved branded products.
NexLife has implemented corrective actions and continues to review medication-related content for regulatory compliance.
Status
Has FDA closed NexLife’s warning letter?
Not as of Nov. 12, 2026: FDA hasn’t published a close-out letter.
Current status: NexLife has implemented corrective actions and continues to review medication-related content for regulatory compliance. As of Nov. 12, 2026, FDA has not published a close-out letter for Warning Letter 730096. NexLife does not state that FDA has formally closed or resolved the matter.
NexLife, Nov. 12, 2026NexLife will update this page if FDA publishes a close-out letter or anything else about Warning Letter 730096.
How FDA closes a warning letter
What is an FDA close-out letter?
FDA may issue a close-out letter after it has evaluated a company’s corrections. The corrective actions, FDA says, “must actually have been made and verified by FDA,” usually through a follow-up inspection, and a close-out letter “will not be issued based on representations that some action will or has been taken.” That’s why a company’s response, on its own, doesn’t close a warning letter.
A close-out letter doesn’t end FDA’s oversight either: if violations are found later, FDA says, “enforcement action may be taken without further notice.” Source: FDA, About Warning and Close-Out Letters.
FDA’s rules for telehealth
What does FDA tell telehealth companies about promoting compounded drugs?
Five practices FDA calls out on its page for telehealth companies.
On its page for telehealth companies (FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs, content current as of June 15, 2026), FDA lists promotion it considers false or misleading, including:
- branding that implies the telehealth company is the compounder;
- describing a compounded drug as a generic version of, or the same as, an FDA-approved drug;
- claiming a compounded drug is FDA-approved, or has otherwise been evaluated for safety and effectiveness;
- describing a compounded drug as clinically proven to produce the same result as the FDA-approved drug; and
- claiming a compounded drug comes from an FDA-approved or FDA-licensed pharmacy or outsourcing facility.
For patients
What does the warning letter mean if you’re a NexLife patient?
The letter is about the website. Here’s who to contact about your care.
FDA’s letter concerns how the nexlife.us website presented compounded semaglutide and tirzepatide: its claims and the labels it pictured. Your prescription is prepared and dispensed by a state-licensed pharmacy.
- Questions about your care or your order: call or text
(949) 818-8000 , 24/7, or email care@nexlife.us. - Questions about this page: email hello@nexlife.us.
- A side effect or a problem with a medicine: tell your provider, and you can also report it to FDA’s MedWatch program, online or at
1-800-FDA-1088 .
Timeline
Warning letter 730096: the timeline
From FDA’s review to today’s status.
March 2026
FDA reviews the nexlife.us website, according to the letter.
June 8, 2026
FDA’s Center for Drug Evaluation and Research issues warning letter MARCS-CMS 730096 to Nexlife Inc. dba Nexlife.
June 16, 2026
FDA posts the letter on its website.
Sept. 21, 2026
NexLife’s most recent formal written response to FDA.
Nov. 12, 2026
Status checked: FDA has not published a close-out letter for Warning Letter 730096.
NexLife’s FDA warning letter: your questions
Did NexLife get an FDA warning letter?
Yes. On June 8, 2026, FDA’s Center for Drug Evaluation and Research issued warning letter MARCS-CMS 730096 to Nexlife Inc. dba Nexlife, after a review of the nexlife.us website in March 2026. FDA posted the letter on its website on June 16, 2026, where anyone can read it in full.
Why did FDA send NexLife a warning letter?
FDA said the website’s representations about compounded semaglutide and tirzepatide were false or misleading. The pictured labels identified “Nexlife,” “suggesting Nexlife is the compounder of those drugs when in fact it is not,” FDA wrote. FDA said that made the products misbranded under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act.
How did NexLife respond to the warning letter?
NexLife submitted a formal written response to FDA, most recently on Sept. 21, 2026. It described corrective actions taken regarding product imagery, website representations, compounded-medication disclosures, and claims concerning FDA approval and FDA-approved branded products. NexLife has implemented corrective actions and continues to review medication-related content for regulatory compliance.
Has FDA closed NexLife’s warning letter?
As of Nov. 12, 2026, FDA has not published a close-out letter for Warning Letter 730096, and NexLife does not state that FDA has formally closed or resolved the matter. FDA says it issues a close-out letter only after the corrective actions have been made and verified by FDA, not on a company’s representations.
Does NexLife make its own medicine?
No. NexLife doesn’t compound, label or dispense medicine. State-licensed partner pharmacies prepare, label and dispense each prescription, after a licensed provider decides treatment is right for the patient. Compounded medicines aren’t FDA-approved, and a provider prescribes one only when it offers a significant difference for that patient.
Is NexLife FDA-approved?
No. FDA approves medicines, not telehealth companies, and the compounded semaglutide and tirzepatide that NexLife’s providers prescribe aren’t FDA-approved either. FDA-approved semaglutide medicines include Wegovy and Ozempic; FDA-approved tirzepatide medicines are Zepbound and Mounjaro. A compounded medicine is prepared by a pharmacy for one patient’s prescription, and it isn’t the same as an FDA-approved brand.
Where can I read FDA’s warning letter to NexLife?
On FDA’s website. Open warning letter MARCS-CMS 730096 directly, or search FDA’s warning letters list for “Nexlife.” The letter is dated June 8, 2026, and FDA posted it on June 16, 2026. It’s linked in the sources at the end of this page.
How do I report a problem with a medicine?
Tell your provider first; NexLife patients can call or text (949) 818-8000, 24/7. You can also report a side effect or a problem with any medicine, compounded ones included, to FDA’s MedWatch program, online at fda.gov/medwatch or by phone at 1-800-FDA-1088 (1-800-332-1088).
Where do I send a question about this page?
Email hello@nexlife.us, or call or text (949) 818-8000, 24/7. If something here is wrong or out of date, tell us and we’ll fix it. NexLife will also update this page if FDA publishes a close-out letter or anything else about Warning Letter 730096.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, constipation and stomach pain.
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who publishes this page, and how we checked it
NexLife is a telehealth and care-coordination platform. It doesn’t compound, label or dispense medicine.
- How we checked. Every quote from the warning letter is from FDA’s posted letter, read on fda.gov on Nov. 12, 2026. FDA’s descriptions of close-out letters and of telehealth promotion are from FDA’s own pages, read the same day, and the law’s wording is from the U.S. Code.
- NexLife’s statements. The response and the status are NexLife’s own statements, as of Nov. 12, 2026.
- Updates. NexLife will update this page if FDA publishes a close-out letter or anything else about Warning Letter 730096.
- Corrections. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
Questions about this page?
Call or text
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
Sources
- U.S. Food and Drug Administration. Warning letter MARCS-CMS 730096 to Nexlife Inc. dba Nexlife. Dated June 8, 2026; posted June 16, 2026. Read Nov. 15, 2026.
- U.S. Food and Drug Administration. About Warning and Close-Out Letters. Content current as of March 20, 2024. Read Nov. 15, 2026.
- U.S. Food and Drug Administration. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs. Content current as of June 15, 2026. Read Nov. 15, 2026.
- U.S. Food and Drug Administration. Warning Letters. Read Nov. 15, 2026.
- 21 U.S.C. 352 (section 502 of the Federal Food, Drug, and Cosmetic Act): misbranded drugs and devices. U.S. Code, 2024 edition. Read Nov. 15, 2026.
- U.S. Food and Drug Administration. Reporting Serious Problems to FDA (MedWatch). Read Nov. 15, 2026.